Show simple item record

dc.contributor.authorChristie, David Rh
dc.contributor.authorSharpley, Christopher F
dc.contributor.authorMitina, Natalia
dc.contributor.authorMacAteer, Eamonn
dc.contributor.authorJackson, James E
dc.contributor.authorLunn, Dominic
dc.date.accessioned2020-08-24T06:08:12Z
dc.date.available2020-08-24T06:08:12Z
dc.date.issued2020
dc.identifier.issn1754-9477
dc.identifier.doi10.1111/1754-9485.13017
dc.identifier.urihttp://hdl.handle.net/10072/396720
dc.description.abstractINTRODUCTION: Neo-adjuvant androgen deprivation therapy prior to radiotherapy (RT) causes shrinkage of the prostate gland, but the changes in volume have never been mapped over time in detail, nor have the associations between volume reduction and testosterone escape or prostate-specific antigen (PSA) kinetics been determined. METHODS: Fifty consecutive patients with prostate cancer were treated with 6 months of triptorelin prior to definitive RT. The volume of the prostate gland was measured at the outset and every 6-7 weeks thereafter using MRI scans. The volumes were calculated using a planimetric method, and inter-rater reliability was checked. Factors associated with a large initial volume and greater reductions in it were assessed. RESULTS: The median volume at the outset was 45 cc, and the median reductions every 6 weeks thereafter were 23, 18, 9 and 5%. The inter-rater agreement was high (r > 0.9, P < 0.001). There were no baseline clinical factors associated with a high initial prostate volume, but the initial volume was associated with greater volume reduction. Testosterone escape had no effect on the reduction, and changes in volume were not reflected in PSA response kinetics. CONCLUSIONS: Reductions in volume continue throughout a 6-month course of neo-adjuvant therapy but are greatest during the first 6 weeks. Although individualisation of the duration or intensity of the hormone treatment warrants further investigation, the role of prostate gland volume reduction remains uncertain. More detailed studies of tumour volume might be possible if the imaging required was acceptable and accessible to patients.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofpagefrom287
dc.relation.ispartofpageto292
dc.relation.ispartofissue2
dc.relation.ispartofjournalJournal of Medical Imaging and Radiation Oncology
dc.relation.ispartofvolume64
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchNursing
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode4205
dc.subject.fieldofresearchcode3211
dc.subject.keywordsgonadotropin-releasing hormone
dc.subject.keywordsmagnetic resonance imaging
dc.subject.keywordsprostate-specific antigen
dc.subject.keywordsradiotherapy
dc.subject.keywordstestosterone
dc.titleIs prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationChristie, DR; Sharpley, CF; Mitina, N; MacAteer, E; Jackson, JE; Lunn, D, Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?, Journal of Medical Imaging and Radiation Oncology, 2020, 64 (2), pp. 287-292
dcterms.dateAccepted2020-02-12
dc.date.updated2020-08-24T06:06:59Z
gro.hasfulltextNo Full Text
gro.griffith.authorChristie, David R.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record